Top

Published in:

01-01-2009 | Review Article

Experiences with recombinant FVIIa in the emergency treatment of patients with autoimmune thrombocytopenia: a review of the literature

Authors: A. Salama, M. Rieke, H. Kiesewetter, M. von Depka

Published in: Annals of Hematology | Issue 1/2009

Abstract

Patients with severe and refractory autoimmune thrombocytopenia (ITP) have significant morbidity and mortality rates. Currently, high-dose methylprednisolone and/or high-dose IVIgG are recommended for the emergency treatment of such patients with uncontrolled bleeding. However, some patients do not immediately respond to these therapeutic regimes and may require additional treatment. Recombinant activated FVIIa (rFVIIa) is a prothrombotic agent that appears to be useful in the treatment of patients with life-threatening bleeding. It has also been used in the treatment of several patients with thrombocytopenia. We administered rFVIIa into a patient with refractory ITP and performed a systemic review of all published reports to assess the available evidence on the efficacy and safety of this drug in patients with ITP. The results indicate that rFVIIa may help in the emergency treatment of patients with ITP who do not respond to other therapies.

Abrahm J, Ellman L (1976) Platelet transfusion in immune thrombocytopenic purpura. JAMA 236:1847 doi:10.1001/jama.236.16.1847a PubMedCrossRef

Aguilar C, Lucía JF (2007) Successful control of severe postoperative bleeding with recombinant factor VIIa in a case of refractory idiopathic thrombocytopenic purpura. Am J Hematol 82:246–247 doi:10.1002/ajh.20728 PubMedCrossRef

Barnes C, Blanchette V, Canning P, Carcao M (2005) Recombinant FVIIa in the management of intracerebral haemorrhage in severe thrombocytopenia unresponsive to platelet-enhancing treatment. Transfus Med 15:145–150 doi:10.1111/j.0958–7578.2005.00564.x PubMedCrossRef

Baumann MA, Menitove JE, Aster RH, Anderson T (1986) Urgent treatment of idiopathic thrombocytopenic purpura with single-dose gammaglobulin infusion followed by platelet transfusion. Ann Intern Med 104:808–809PubMed

Baxter MS, Schroeder WS, Cheng Y, Bernstein ZP (2006) Diminished response to recombinant factor VIIa in a patient with idiopathic thrombocytopenic purpura. Ann Pharmacother 40:2053–2058 doi:10.1345/aph.1H331 PubMedCrossRef

Bay A, Oner AF, Etlik O, Caksen H (2005) A case of immune thrombocytopenic purpura presenting with recurrent intracranial hemorrhage. Pediatr Int 47:109–111 doi:10.1111/j.1442-200x.2005.02014.x PubMedCrossRef

Blanchette V, Freedman J, Garvey B (1998) Management of chronic immune thrombocytopenic purpura in children and adults. Semin Hematol 35:36–51PubMed

Busani S, Marietta M, Pasetto A, Girardis M (2005) Use of recombinant factor VIIa in a thrombocytopenic patient with spontaneous intracerebral haemorrhage. Thromb Haemost 93:381–382PubMed

Bussel JB, Kimberly RP, Inman RD, Schulman I, Cunningham-Rundles C, Cheung N et al (1983) Intravenous gammaglobulin treatment of chronic idiopathic thrombocytopenic purpura. Blood 62:480–486PubMed

10.

Carr JM, Kruskall MS, Kaye JA, Robinson SH (1986) Efficacy of platelet transfusions in immune thrombocytopenia. Am J Med 80:1051–1054 doi:10.1016/0002-9343(86)90664-9 PubMedCrossRef

11.

Chandramouli NB, Rodgers GM (2000) Prolonged immunoglobulin and platelet infusion for treatment of immune thrombocytopenia. Am J Hematol 65:85–86 doi:10.1002/1096-8652(200009)65:1<85::AID-AJH17>3.0.CO;2-9 PubMedCrossRef

12.

Cines DB, Blanchette VS (2002) Immune thrombocytopenic purpura. N Engl J Med 346:995–1008 doi:10.1056/NEJMra010501 PubMedCrossRef

13.

Cines DB, McMillan R (2005) Management of adult idiopathic thrombocytopenic purpura. Annu Rev Med 56:425–442 doi:10.1146/annurev.med.56.082103.104644 PubMedCrossRef

14.

Crosby WH (1975) Editorial: wet purpura, dry purpura. JAMA 232:744–745 doi:10.1001/jama.232.7.744 PubMedCrossRef

15.

Culic S (2002) Recombinant factor VIIa for refractive haemorrhage in autoimmune idiopathic thrombocytopenic purpura. Br J Haematol 120:909–910 doi:10.1046/j.1365-2141.2003.04151_2.x CrossRef

16.

Frederiksen H, Schmidt K (1999) The incidence of idiopathic thrombocytopenic purpura in adults increases with age. Blood 94:909–913PubMed

17.

Friederich PW, Henny CP, Messelink EJ, Geerdink MG, Keller T, Kurth KH et al (2003) Effect of recombinant activated factor VII on perioperative blood loss in patients undergoing retropubic prostatectomy: a double-blind placebo-controlled randomised trial. Lancet 361:201–205 doi:10.1016/S0140-6736(03)12268-4 PubMedCrossRef

18.

George JN, Woolf SH, Raskob GE, Wasser JS, Aledort LM, Ballem PJ et al (1996) Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood 88:3–40PubMed

19.

Gerotziafas GT, Zervas C, Gavrielidis G, Tokmaktsis A, Hatjiharissi E, Papaioannou M et al (2002) Effective hemostasis with rFVIIa treatment in two patients with severe thrombocytopenia and life-threatening hemorrhage. Am J Hematol 69:219–222 doi:10.1002/ajh.10056 PubMedCrossRef

20.

Goodnough LT (2004) Experiences with recombinant human factor VIIa in patients with thrombocytopenia. Semin Hematol 41:25–29 doi:10.1053/j.seminhematol.2003.11.006 PubMedCrossRef

21.

Hadacova I, Hoch J (2003) Activated factor VII as the perioperative guarrancy of splenectomy for severe form of corticoresistant ITP. Prakt Lek 83:695–696

22.

Hoffman M, Monroe DM, Roberts HR (1998) Activated factor VII activates factors IX and X on the surface of activated platelets: thoughts on the mechanism of action of high dose activated FVII. Blood Coagul Fibrinolysis 9:S61–S65PubMed

23.

Imbach P, Barandun S, D’Apuzzo V, Baumgartner C, Hirt A, Morell A et al (1981) High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1:1228–1231 doi:10.1016/S0140-6736(81)92400-4 PubMedCrossRef

24.

Ingerslev J, Holm M, Christiansen K, Knudsen L, Négrier C (1998) Levels of prothrombin activation peptide F1 + 2 in patients with bleeding tendency. Blood Coagul Fibrinolysis 9:S129–S134 doi:10.1097/00001721-199803000-00003 PubMedCrossRef

25.

Kiefel V, Santoso S, Kaufmann E, Mueller-Eckhardt C (1991) Autoantibodies against platelet glycoprotein lb/IX: a frequent finding in autoimmune thrombocytopenic purpura. Br J Haematol 79:256–262 doi:10.1111/j.1365-2141.1991.tb04530.x PubMedCrossRef

26.

Klamroth R, Gottstein S, Landgraf H (2002) Successful use of recombinant factor VIIa to prevent bleeding during major surgery in a patient with severe immune thrombocytopenia. Blood 100:77b

27.

Kristensen J, Killander A, Hippe E, Helleberg C, Ellegard J, Holm M et al (1996) Clinical experience with recombinant factor VIIa in patients with thrombocytopenia. Haemostasis 26:159–164PubMed

28.

Kubisz P, Stasko J (2004) Recombinant activated factor VII in patients at high risk of bleeding. Hematology 9:317–332 doi:10.1080/10245330400018581 PubMedCrossRef

29.

Levi M, Peters M, Büller HR (2005) Efficacy and safety of recombinant factor VIIa for treatment of severe bleeding: a systematic review. Crit Care Med 33:883–890 doi:10.1097/01.CCM.0000159087.85970.38 PubMedCrossRef

30.

McMillan R, Tani P, Millard F, Berchtold P, Renshaw L, Woods VL Jr (2005) Platelet-associated and plasma anti-glycoprotein autoantibodies in chronic ITP. Blood 70:1040–1045

31.

McMillan R (1997) Therapy for adults with refractory chronic immune thrombocytopenic purpura. Ann Intern Med 126:307–314PubMed

32.

Meyer O, Agaylan A, Bombard S, Kiesewetter H, Salama A (2006) A novel antigen-specific capture assay for the detection of platelet antibodies and HPA-1a phenotyping. Vox Sang 91:324–330 doi:10.1111/j.1423-0410.2006.00839.x PubMedCrossRef

33.

Minniti C, Weinthal J (2001) Use of recombinant activated factor VII (rFVIIa) in two children with idiopathic thrombocytopenic purpura (ITP). Blood 98:62b

34.

Monroe DM, Hoffman M, Oliver JA, Roberts HR (1997) Platelet activity of high dose factor VIIa is independent of tissue factor. Br J Haematol 99:542–547 doi:10.1046/j.1365-2141.1997.4463256.x PubMedCrossRef

35.

Morath C, Hoffmann T, Kirchhoff EM, Sis J, Zeier M, Scharf RE et al (2005) Acquired Glanzmann's thrombasthenia variant and immune thrombocytopenia in a renal transplant recipient receiving tacrolimus. Thromb Haemost 94:879–880PubMed

36.

Portielje JEA, Westendorp RGJ, Kluin-Nelemans HC, Brand A (2001) Morbidity and mortality in adults with idiopathic thrombocytopenic purpura. Blood 97:2549–2554 doi:10.1182/blood.V97.9.2549 PubMedCrossRef

37.

Provan D, Newland A (2002) Fifty years of idiopathic thrombocytopenic purpura (ITP): Management of refractory ITP in adults. Br J Haematol 118:933–944 doi:10.1046/j.1365-2141.2002.03669.x PubMedCrossRef

38.

Rao LVM, Williams T, Rapaport SI (1996) Studies on the activation of factor VII bound to tissue factor. Blood 87:3738–3748PubMed

39.

Roberts HR (1998) Clinical experience with activated factor VII: focus on safety aspects. Blood Coagul Fibrinolysis 9:S115–S118PubMed

40.

Serban M, Petrescu CAM, Jinca C, Mihalov D (2003) Evaluation of the rFVIIa efficacy in children’s haemorrhages of different etiology. J Thromb Haemost 1(Suppl.):1144 doi:10.1046/j.1538-7836.2003.00144.x

41.

Van Leeuwen EF, van der Ven JT, Engelfriet CP, von dem Borne AE (1982) Specifity of autoantibodies in autoimmune thrombocytopenia. Blood 59:23–36PubMed

42.

Vidarsson B, Onundarson PT (2000) Recombinant factor VIIa for bleeding in refractory thrombocytopenia. Thromb Haemost 83:634–635PubMed

43.

Virchis A, Hughes C, Berney S (2004) Severe gastrointeral haemorrhage responding to recombinant factor VIIa in a Jehova’s Witness with refractory immune thrombocytopenia. Hematol J 5:281–282 doi:10.1038/sj.thj.6200395 PubMedCrossRef

44.

Vyhovs’ka II, Karol’ IS, Fedak LM, Tsytsyk OI (2004) Use of recombinant activated factor VII (NovoSeven) in the treatment of a patient with idiopathic thrombocytopenic purpura complicated with subarachnoid and parenchimatous hemorrhage. Lik Sprava 7:77–81PubMed

45.

Waddington DP, McAuley FT, Hanley JP, Summerfield GP (2002) The use of recombinant factor VIIa in a Jehovah's witness with auto-immune thrombocytopenia and post-splenectomy haemorrhage. Br J Haematol 119:286–288 doi:10.1046/j.1365-2141.2002.381113.x PubMedCrossRef

46.

Wróbel G, Dobaczewski G, Patkowski D, Sokół A, Grotthus E (2006) Experiences with recombinant activated factor VII in the treatment of severe refractory thrombocytopenia. Pediatr Blood Cancer 47:729–730 doi:10.1002/pbc.21013 PubMedCrossRef

47.

Yoneoka Y, Tokita K, Yamauchi JI, Takeda N, Ohta H, Shindo T (2004) Successful management for spontaneous intracranial haemorrhage under critical thrombocytopenia (platelets <1000/mm(3)) due to adolescence-onset idiopathic thrombocytopenic purpura. Acta Neurochir (Wien) 146:199–201 doi:10.1007/s00701-003-0185-0 CrossRef

Title: Experiences with recombinant FVIIa in the emergency treatment of patients with autoimmune thrombocytopenia: a review of the literature
Authors: A. Salama
M. Rieke
H. Kiesewetter
M. von Depka
Publication date: 01-01-2009
Publisher: Springer-Verlag
Published in: Annals of Hematology / Issue 1/2009
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI: https://doi.org/10.1007/s00277-008-0608-3

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2009

The 19-bp deletion of dihydrofolate reductase (DHFR), methylenetetrahydrofolate reductase (MTHFR) C677T, Factor V Leiden, prothrombin G20210A polymorphisms in cancer patients with and without thrombosis

Successful treatment of Candida spp. encephalitis occurring under Caspofungin treatment after allogeneic stem cell transplantation

An unusual presentation of eosinophilic variant of chronic myeloid leukemia (eoCML)

Flow cytometric assay of phosphotyrosine levels in Bcr-Abl-positive chronic myelogenous leukemias: a potential prognostic marker

Double-faced cell-mediated immunity in β-thalassemia major: stimulated phenotype versus suppressed activity

Patients with iron deficiency anemia have an increased prevalence of gallstones

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials